Nebicard (Nebivolol Hydrochloride)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which reduces heart rate and contractility, while simultaneously stimulating endothelial nitric‑oxide synthase to cause vasodilation. This dual action decreases cardiac output and peripheral resistance, leading to lowered arterial pressure and enhanced cardiac efficiency.

The dosage of Nebicard is individualized; a qualified prescriber determines the appropriate strength and regimen based on the patient’s blood pressure, heart‑failure status, age, renal function and concomitant therapies. Patients should follow the prescribing information and not adjust the dose without medical advice.

Safety data for nebivolol during pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nebicard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective beta‑blockers, nebivolol offers additional nitric‑oxide‑mediated vasodilation, which may improve endothelial function and cause fewer metabolic side effects. It is often considered alongside ACE inhibitors, ARBs or calcium‑channel blockers, with choice guided by patient comorbidities and tolerability.

Nebicard tablets should be stored at ambient temperature, below 25 °C, in the original blister or bottle, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiration date.

Nebicard is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed.

The most serious adverse events include severe bradycardia, symptomatic hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat changes, difficulty breathing, or swelling.

Nebicard is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or severe asthma/COPD. It should also be used with caution in patients with hepatic or renal impairment.